Effect of the SARS-CoV-2 pandemic on colorectal cancer diagnosis and prognosis

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Medina-Prado, Lucia
- Sala-Miquel, Noelia
- Aicart-Ramos, Marta
- Lopez-Cardona, Julia
- Ponce-Romero, Marta
- Ortiz, Oswaldo
- Pellise, Maria
- Aguilera, Lara
- Diez-Redondo, Pilar
- Nunez-Rodriguez, Henar
- Seoane, Agustin
- Domper-Arnal, Maria-Jose
- Borao-Laguna, Cristina
- Gonzalez-Bernardo, Oscar
- Suarez, Adolfo
- Munoz-Tornero, Maria
- Balleste-Peris, Belen
- Esteban, Pilar
- Jimenez-Gomez, Mirella
- Albert, Marc
- Lucas, Javier
- Valdivieso-Cortazar, Eduardo
- Lopez-Serrano, Antonio
- Solano, Marina
- Tejedor-Tejada, Javier
- Trelles, Marita
- Zapater, Pedro
- Jover, Rodrigo
Grupos
Abstract
Background and Study AimsOur aim was to determine the impact of the SARS-CoV-2 pandemic on the diagnosis and prognosis of colorectal cancer (CRC).Patients and MethodsThis prospective cohort study included individuals diagnosed with CRC between March 13, 2019 and June 20, 2021 across 21 Spanish hospitals. Two time periods were compared: prepandemic (from March 13, 2019 to March 13, 2020) and pandemic (from March 14, 2020 to June 20, 2021, lockdown period and 1 year after lockdown).ResultsWe observed a 46.9% decrease in the number of CRC diagnoses (95% confidence interval (CI): 45.1%-48.7%) during the lockdown and 29.7% decrease (95% CI: 28.1%-31.4%) in the year after the lockdown. The proportion of patients diagnosed at stage I significantly decreased during the pandemic (21.7% vs. 19.0%; p = 0.025). Centers that applied universal preprocedure SARS-CoV-2 PCR testing experienced a higher reduction in the number of colonoscopies performed during the pandemic post-lockdown (34.0% reduction; 95% CI: 33.6%-34.4% vs. 13.7; 95% CI: 13.4%-13.9%) and in the number of CRCs diagnosed (34.1% reduction; 95% CI: 31.4%-36.8% vs. 26.7%; 95% CI: 24.6%-28.8%). Curative treatment was received by 87.5% of patients diagnosed with rectal cancer prepandemic and 80.7% of patients during the pandemic post-lockdown period (p = 0.002).ConclusionsThe COVID-19 pandemic has led to a decrease in the number of diagnosed CRC cases and in the proportion of stage I CRC. The reduction in the number of colonoscopies and CRC diagnoses was higher in centers that applied universal SARS-CoV-2 PCR screening before colonoscopy. In addition, the COVID-19 pandemic has affected curative treatment of rectal cancers.
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 2045-7634, 2045-7634
- Tipo:
- Article
- Páginas:
- -
- DOI:
- 10.1002/cam4.6923
- PubMed:
- 38491824
- Factor de Impacto:
- 1,144 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Cancer Medicine WILEY
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Keywords
- COVID-19 pandemic; endoscopy; screening colonoscopy
Proyectos y Estudios Clínicos
Desarrollo de endofis, un nuevo producto sanitario para el tratamiento endoscópico de las fístulas posquirúrgicas del tracto digestivo.
Investigador Principal: VICENTE MARÍA LORENZO-ZÚÑIGA GARCÍA
PI21/00193 . INSTITUTO DE SALUD CARLOS III . 2022
CIERRE DE DEFECTOS MUCOSOS CON CLIPS TRAS RESECCIÓN ENDOSCÓPICA MUCOSA DE LESIONES COLORRECTALES DE GRAN TAMAÑO COMO PROFILAXIS DE HEMORRAGIA DIFERIDA.
Investigador Principal: MARCO BUSTAMANTE BALÉN
FMSALBE
ENSAYO CLÍNICO DOBLE CIEGO, CONTROLADO CON PLACEBO, SOBRE LA EFICACIA DE LA ABLACIÓN ANTIRREFLUJO DE LA MUCOSA DEL CARDIAS PARA EL TRATAMIENTO DE LA ENFERMEDAD POR REFLUJO GASTROESOFÁGICO.
Investigador Principal: VICENTE MARÍA LORENZO-ZÚÑIGA GARCÍA
ECA-HRC-ARMA . 2021
Eficacia y rentabilidad de un sistema de inteligencia artificial (GI-Genius) en la caracterización de pólipos colorrectales diminutos dentro de un programa de cribado de cáncer colorrectal (ODDITY trial)
Investigador Principal: MARCO BUSTAMANTE BALÉN
2023_1013_1_SVPD_MARCO . SVPD SOCIEDAD VALENCIANA PATOLOGIA DIGESTIVA . 2023